Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $151.84 million. The enterprise value is $102.77 million.
| Market Cap | 151.84M |
| Enterprise Value | 102.77M |
Important Dates
The last earnings date was Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 240.63 million shares outstanding. The number of shares has increased by 13.96% in one year.
| Current Share Class | 240.63M |
| Shares Outstanding | 240.63M |
| Shares Change (YoY) | +13.96% |
| Shares Change (QoQ) | +3.16% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 0.17% |
| Float | 238.23M |
Valuation Ratios
The trailing PE ratio is 9.01 and the forward PE ratio is 2.18.
| PE Ratio | 9.01 |
| Forward PE | 2.18 |
| PS Ratio | 0.65 |
| Forward PS | 0.49 |
| PB Ratio | 1.75 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | 20.28 |
| P/OCF Ratio | 19.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.86, with an EV/FCF ratio of 13.58.
| EV / Earnings | 6.29 |
| EV / Sales | 0.43 |
| EV / EBITDA | 3.86 |
| EV / EBIT | 5.69 |
| EV / FCF | 13.58 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.57 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 1.72 |
| Interest Coverage | 6.40 |
Financial Efficiency
Return on equity (ROE) is 22.26% and return on invested capital (ROIC) is 65.10%.
| Return on Equity (ROE) | 22.26% |
| Return on Assets (ROA) | 6.41% |
| Return on Invested Capital (ROIC) | 65.10% |
| Return on Capital Employed (ROCE) | 18.20% |
| Weighted Average Cost of Capital (WACC) | 11.82% |
| Revenue Per Employee | $2.26M |
| Profits Per Employee | $155,495 |
| Employee Count | 105 |
| Asset Turnover | 1.35 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $476,000 in taxes.
| Income Tax | 476,000 |
| Effective Tax Rate | 2.83% |
Stock Price Statistics
The stock price has increased by +8.05% in the last 52 weeks. The beta is 1.23, so Vaxart's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +8.05% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 45.26 |
| Average Volume (20 Days) | 684,364 |
Short Selling Information
The latest short interest is 21.17 million, so 8.80% of the outstanding shares have been sold short.
| Short Interest | 21.17M |
| Short Previous Month | 14.68M |
| Short % of Shares Out | 8.80% |
| Short % of Float | 8.89% |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Vaxart had revenue of $237.26 million and earned $16.33 million in profits. Earnings per share was $0.07.
| Revenue | 237.26M |
| Gross Profit | 35.68M |
| Operating Income | 18.07M |
| Pretax Income | 16.80M |
| Net Income | 16.33M |
| EBITDA | 26.65M |
| EBIT | 18.07M |
| Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $63.81 million in cash and $13.05 million in debt, with a net cash position of $50.76 million or $0.21 per share.
| Cash & Cash Equivalents | 63.81M |
| Total Debt | 13.05M |
| Net Cash | 50.76M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 87.80M |
| Book Value Per Share | 0.37 |
| Working Capital | 49.37M |
Cash Flow
In the last 12 months, operating cash flow was $7.71 million and capital expenditures -$145,000, giving a free cash flow of $7.57 million.
| Operating Cash Flow | 7.71M |
| Capital Expenditures | -145,000 |
| Depreciation & Amortization | 8.58M |
| Net Borrowing | n/a |
| Free Cash Flow | 7.57M |
| FCF Per Share | $0.03 |
Margins
Gross margin is 15.04%, with operating and profit margins of 7.62% and 6.88%.
| Gross Margin | 15.04% |
| Operating Margin | 7.62% |
| Pretax Margin | 7.08% |
| Profit Margin | 6.88% |
| EBITDA Margin | 11.23% |
| EBIT Margin | 7.62% |
| FCF Margin | 3.19% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.96% |
| Shareholder Yield | -13.96% |
| Earnings Yield | 10.63% |
| FCF Yield | 4.93% |
Analyst Forecast
The average price target for Vaxart is $2.00, which is 216.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 216.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | -45.68% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -0.92 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.92 |
| Piotroski F-Score | 6 |